BPC-157 + TB-500
The body's repair signal, amplified.
Vial content, not a dose.
BPC-157 is a synthetic 15-amino-acid pentadecapeptide, its sequence drawn from a partial segment of a protein found in human gastric juice — the "Body Protection Compound" it takes its name from. TB-500 is a shorter synthetic fragment, Ac-LKKTETQ, corresponding to the actin-binding region of thymosin beta-4, a 43-amino-acid protein present in most human cells. This vial holds 5 mg of each, which is vial content and not a dose. Both are studied for their roles in tissue-repair signaling.
Repair is not a capacity the body has to be given. It is a sequence it already runs — vessels recruited, cells moved into place, tissue rebuilt — and one that becomes less prompt as hormonal and metabolic patterns shift. Both peptides in this vial are studied along that same existing sequence, as a reminder of it rather than a substitute for it.
How the signal travels.
The two are studied along different but adjacent routes. BPC-157 appears in the literature mostly at the level of blood vessels and local signaling; TB-500 at the level of the cell's internal scaffolding.
Animal work describes BPC-157 as acting through the nitric-oxide system — a pathway the body already uses to regulate vascular tone and local blood flow around damaged tissue.
Preclinical studies link BPC-157 to the VEGFR2–Akt–eNOS cascade, associated with new vessel formation, and to FAK–paxillin signaling, associated with how cells attach and migrate.
TB-500 corresponds to residues 17–23 of thymosin beta-4, the actin-binding region of an actin-sequestering protein found in most human cells. Actin regulation governs how cells change shape and move.
In animal models, TB-500 is studied alongside Akt/mTOR signaling and the upregulation of VEGF and angiopoietin-1, with reported effects on wound closure and the degree of fibrosis.
What it's used to support.
For women 35+ who are active, rehabilitating a soft-tissue injury, or noticing that recovery from ordinary strain takes longer than it once did. It suits those who want to understand a mechanism and its evidence limits before beginning, and who are comfortable knowing this pairing sits squarely in preclinical research.
The figures above are the amount of lyophilized peptide in the vial — they are not a dose. Your protocol, timing, and duration are set one-to-one with a licensed practitioner based on your history and goals.
What's actually in the vial.
This is a combined-vial formulation. Each figure below is that component's share of the vial content — not a dose.
The specifics, if you want them.
Technical specifications
Where the research stands
The evidence here is preclinical. BPC-157 rests on over a hundred animal studies, most from a single Croatian laboratory, with essentially no completed controlled human trials — a 2025 systematic review of the orthopaedic literature found only one clinical study among them, and no clinical safety data at all. TB-500's human research concerns its full-length parent protein, not this fragment.
Storage & handling
Before you start.
We don't publish a route, a schedule, or an amount for this pairing. The 5 mg and 5 mg on the label describe what is in the vial, not what anyone takes. Administration, frequency, and duration are settled one-to-one with a licensed practitioner during consultation, against your history and the tissue involved.
No window goes on this page, because none of the research supports one. Repair depends on tissue type, the nature of the strain, and your own physiology — and beyond that, the human evidence base for this pairing simply isn't there to draw one from. Your practitioner can set expectations for your situation and tell you what is worth tracking.
Yes. This is not a pairing to begin on your own. A licensed practitioner should review your health history, weigh the preclinical nature of the research against what you are trying to achieve, and confirm whether it is an appropriate fit before anything begins — and stay involved once it does.
No, and the distinction matters. TB-500 is a seven-residue synthetic fragment, Ac-LKKTETQ, corresponding to residues 17–23 of thymosin beta-4 — the actin-binding region of a 43-amino-acid protein. The two are often listed interchangeably, but they are not interchangeable. Most existing human research concerns the full-length protein; this vial contains the fragment.
They are studied along adjacent parts of the same repair sequence. Preclinical work on BPC-157 centres on nitric-oxide and vascular signaling and on gut tissue; work on TB-500 centres on actin regulation and cell migration. Pairing them covers more of that sequence — though the pairing itself has not been examined in controlled human trials.
Every Inner Peptides formula is independently tested before it ships, with a Certificate of Analysis available on request. Learn more about our testing standard.
